Genentech Manufacturing Deal With Lonza Provides For Future Biologic Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech plans to sell its 40,000-liter facility in Spain to Lonza, while in turn gaining the option to buy Lonza’s 80,000-liter facility in Singapore.
You may also be interested in...
Biogen Tysabri Facility Will Shift To Avastin Production Under New Owner
Genentech agreed to pay Biogen $408.1 mil. for its southern California Tysabri facility to add capacity for Avastin. The facility was undergoing validation; Biogen expected to begin selling the multiple sclerosis therapy out of the facility by 2006.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.